{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T14:42:04Z","timestamp":1785595324228,"version":"3.56.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T00:00:00Z","timestamp":1628467200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","valueinhealthjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.jval.2021.04.1281","type":"journal-article","created":{"date-parts":[[2021,7,25]],"date-time":"2021-07-25T06:58:37Z","timestamp":1627196317000},"page":"1446-1453","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Social Impact of Prophylactic Migraine Treatments in Germany: A State-Transition and Open Cohort Approach"],"prefix":"10.1016","volume":"24","author":[{"given":"Ahmed H.","family":"Seddik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Schiener","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis A.","family":"Ostwald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Schramm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasper","family":"Huels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaza","family":"Katsarava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jval.2021.04.1281_bib1","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/j.1468-2982.2007.01288.x","article-title":"The global burden of headache: a documentation of headache prevalence and disability worldwide","volume":"27","author":"Stovner","year":"2007","journal-title":"Cephalalgia"},{"issue":"9","key":"10.1016\/j.jval.2021.04.1281_bib2","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1177\/0333102413485658","article-title":"The International Classification of Headache Disorders, 3rd ed (beta version)","volume":"33","year":"2013","journal-title":"Cephalalgia"},{"issue":"5","key":"10.1016\/j.jval.2021.04.1281_bib4","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1474-4422(18)30499-X","article-title":"Global, regional, and national burden of migraine and tension-type headache, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016","volume":"18","year":"2019","journal-title":"Lancet Neurol"},{"issue":"1","key":"10.1016\/j.jval.2021.04.1281_bib5","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s10194-018-0907-6","article-title":"Patients\u2019 perspective on the burden of migraine in Europe: a cross-sectional analysis of survey data in France, Germany, Italy, Spain, and the United Kingdom","volume":"19","author":"Vo","year":"2018","journal-title":"J\u00a0Headache Pain"},{"issue":"5","key":"10.1016\/j.jval.2021.04.1281_bib6","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1111\/j.1468-1331.2011.03612.x","article-title":"The cost of headache disorders in Europe: the Eurolight project","volume":"19","author":"Linde","year":"2012","journal-title":"Eur J Neurol"},{"issue":"Suppl 1","key":"10.1016\/j.jval.2021.04.1281_bib7","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/head.13301","article-title":"Migraine burden of disease: from the patient\u2019s experience to a socio-economic view","volume":"58","author":"Agosti","year":"2018","journal-title":"Headache"},{"issue":"14","key":"10.1016\/j.jval.2021.04.1281_bib8","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1177\/0333102420944842","article-title":"The socioeconomic burden of migraine: an evaluation of productivity losses due to migraine headaches based on a population study in Germany","volume":"40","author":"Seddik","year":"2020","journal-title":"Cephalalgia"},{"issue":"Suppl 2","key":"10.1016\/j.jval.2021.04.1281_bib9","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/head.12505_2","article-title":"Episodic and chronic migraine headache: breaking down barriers to optimal treatment and prevention","volume":"55","author":"Lipton","year":"2015","journal-title":"Headache"},{"issue":"22","key":"10.1016\/j.jval.2021.04.1281_bib11","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa1705848","article-title":"A\u00a0controlled trial of Erenumab for episodic migraine","volume":"377","author":"Goadsby","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jval.2021.04.1281_bib12","doi-asserted-by":"crossref","first-page":"363","DOI":"10.3389\/fphar.2019.00363","article-title":"New trends in migraine pharmacology: targeting calcitonin gene\u2013related peptide (CGRP) with monoclonal antibodies","volume":"10","author":"Scuteri","year":"2019","journal-title":"Front Pharmacol"},{"issue":"4 Headache","key":"10.1016\/j.jval.2021.04.1281_bib13","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1212\/CON.0000000000000199","article-title":"Preventive migraine treatment","volume":"21","author":"Silberstein","year":"2015","journal-title":"Continuum (Minneap Minn)"},{"issue":"6","key":"10.1016\/j.jval.2021.04.1281_bib14","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S1474-4422(17)30083-2","article-title":"Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial","volume":"16","author":"Tepper","year":"2017","journal-title":"Lancet Neurol"},{"issue":"10161","key":"10.1016\/j.jval.2021.04.1281_bib15","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1016\/S0140-6736(18)32534-0","article-title":"Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study","volume":"392","author":"Reuter","year":"2018","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.jval.2021.04.1281_bib16","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1177\/0333102418759786","article-title":"ARISE: a phase 3 randomized trial of erenumab for episodic migraine","volume":"38","author":"Dodick","year":"2018","journal-title":"Cephalalgia"},{"key":"10.1016\/j.jval.2021.04.1281_bib17","author":"Diener"},{"issue":"4","key":"10.1016\/j.jval.2021.04.1281_bib18","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1080\/14737167.2019.1644169","article-title":"A\u00a0case study applying a novel approach to estimate the social impact of a medical innovation - the use of secukinumab for psoriatic arthritis in Germany","volume":"20","author":"Himmler","year":"2020","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"10.1016\/j.jval.2021.04.1281_bib19","series-title":"Encyclopedia of Medical Decision Making","article-title":"Human capital approach","author":"Grosse","year":"2009"},{"issue":"3","key":"10.1016\/j.jval.2021.04.1281_bib20","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s10194-012-0425-x","article-title":"Prevalence of primary headaches in Germany: results of the German Headache Consortium Study","volume":"13","author":"Yoon","year":"2012","journal-title":"J\u00a0Headache Pain"},{"key":"10.1016\/j.jval.2021.04.1281_bib21","series-title":"Clinical Neurology of the Older Adult","year":"2008"},{"issue":"10","key":"10.1016\/j.jval.2021.04.1281_bib22","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1177\/0333102418789072","article-title":"Migraine-related disability, impact, and health-related quality of life among patients with episodic migraine receiving preventive treatment with erenumab","volume":"38","author":"Buse","year":"2018","journal-title":"Cephalalgia"},{"key":"10.1016\/j.jval.2021.04.1281_bib23","series-title":"Bev\u00f6lkerung Deutschlands Bis 2060 - Tabellenband - Ergebnisse Der 13","year":"2015"},{"issue":"2","key":"10.1016\/j.jval.2021.04.1281_bib24","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2217\/cer-2020-0077","article-title":"The societal impact of a biologic treatment of ankylosing spondylitis: a case study based on secukinumab","volume":"10","author":"Himmler","year":"2021","journal-title":"J\u00a0Comp Eff Res"},{"key":"10.1016\/j.jval.2021.04.1281_bib26","first-page":"382","volume":"6","author":"Haag","year":"2009","journal-title":"Nervenheilkunde"},{"issue":"1","key":"10.1016\/j.jval.2021.04.1281_bib28","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.jval.2013.08.2291","article-title":"Budget impact analysis-principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force","volume":"17","author":"Sullivan","year":"2014","journal-title":"Value Health"},{"issue":"4","key":"10.1016\/j.jval.2021.04.1281_bib29","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/j.1524-4733.2004.74002.x","article-title":"Discounting health outcomes in economic evaluation: the ongoing debate","volume":"7","author":"Severens","year":"2004","journal-title":"Value Health"},{"key":"10.1016\/j.jval.2021.04.1281_bib30","author":"Goodman"},{"issue":"1","key":"10.1016\/j.jval.2021.04.1281_bib31","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s10194-019-1018-8","article-title":"Erenumab and galcanezumab in chronic migraine prevention: effects after treatment termination","volume":"20","author":"Raffaelli","year":"2019","journal-title":"J\u00a0Headache Pain"},{"issue":"11","key":"10.1016\/j.jval.2021.04.1281_bib32","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1177\/0333102419854082","article-title":"Long-term safety and tolerability of erenumab: three-plus year results from a five-year open-label extension study in episodic migraine","volume":"39","author":"Ashina","year":"2019","journal-title":"Cephalalgia"},{"issue":"1","key":"10.1016\/j.jval.2021.04.1281_bib33","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s12955-018-0871-5","article-title":"Translation, cross-cultural adaptation and reliability of the German version of the migraine disability assessment (MIDAS) questionnaire","volume":"16","author":"Benz","year":"2018","journal-title":"Health Qual Life Outcomes"},{"issue":"6","key":"10.1016\/j.jval.2021.04.1281_bib34","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/j.1468-2982.2004.00703.x","article-title":"Attitudes and burden of disease among self-considered migraineurs \u2014 a nation-wide population-based survey in Sweden","volume":"24","author":"Linde","year":"2004","journal-title":"Cephalalgia"},{"key":"10.1016\/j.jval.2021.04.1281_bib35","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s10194-016-0599-8","article-title":"Interictal burden attributable to episodic headache: findings from the Eurolight project","volume":"17","author":"Lampl","year":"2016","journal-title":"J\u00a0Headache Pain"},{"issue":"1","key":"10.1016\/j.jval.2021.04.1281_bib36","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/j.1468-2982.2007.01469.x","article-title":"Migraine incidence, comorbidity and health resource utilization in the UK","volume":"28","author":"Becker","year":"2008","journal-title":"Cephalalgia"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301521015357?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301521015357?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T01:24:26Z","timestamp":1761096266000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301521015357"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":32,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["S1098301521015357"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2021.04.1281","relation":{},"ISSN":["1098-3015"],"issn-type":[{"value":"1098-3015","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Social Impact of Prophylactic Migraine Treatments in Germany: A State-Transition and Open Cohort Approach","name":"articletitle","label":"Article Title"},{"value":"Value in Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jval.2021.04.1281","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 ISPOR-The Professional Society for Health Economics and Outcomes Research. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}